Next Article in Journal
TGF-β Increases MFGE8 Production in Myeloid-Derived Suppressor Cells to Promote B16F10 Melanoma Metastasis
Previous Article in Journal
Enzymes in the Cholesterol Synthesis Pathway: Interactomics in the Cancer Context
Previous Article in Special Issue
Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Colorectal Cancer, Liver Metastases and Biotherapies

by
Daniel-Clement Osei-Bordom
1,2,3,
Sivesh Kamarajah
1 and
Niki Christou
1,4,5,*
1
Department of General Surgery, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham B15 2TH, UK
2
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK
3
NIHR Birmingham Biomedical Research Centre, Centre for Liver and Gastroenterology Research, University of Birmingham, Birmingham B15 2TT, UK
4
Department of General Surgery, University Hospital of Limoges, 87000 Limoges, France
5
EA3842 CAPTuR Laboratory “Cell Activation Control, Tumor Progression and Therapeutic Resistance”, Faculty of Medicine, 2 Rue du Docteur Marcland, 87025 Limoges, France
*
Author to whom correspondence should be addressed.
Biomedicines 2021, 9(8), 894; https://doi.org/10.3390/biomedicines9080894
Submission received: 18 June 2021 / Revised: 13 July 2021 / Accepted: 21 July 2021 / Published: 26 July 2021
(This article belongs to the Special Issue Liver Cancers: From Bench to Bedside)

Abstract

(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide. Its first main metastatic diffusion spreads to the liver. Different mechanisms such as the epithelial–mesenchymal transition and angiogenesis are the characteristics of this invasion. At this stage, different options are possible and still in debate, especially regarding the use of targeted therapeutics and biotherapies. (2) Methods: A review of the literature has been done focusing on the clinical management of liver metastasis of colorectal cancer and the contribution of biotherapies in this field. (3) Results: In a clinical setting, surgeons and oncologists consider liver metastasis in CRC into two groups to launch adapted therapeutics: resectable and non-resectable. Around these two entities, the combination of targeted therapies and biotherapies are of high interest and are currently tested to know in which molecular and clinical conditions they have to be applied to impact positively both on survival and quality of life of patients.
Keywords: colorectal cancer; liver metastases; immunotherapy; chemotherapy and biological agents colorectal cancer; liver metastases; immunotherapy; chemotherapy and biological agents

Share and Cite

MDPI and ACS Style

Osei-Bordom, D.-C.; Kamarajah, S.; Christou, N. Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines 2021, 9, 894. https://doi.org/10.3390/biomedicines9080894

AMA Style

Osei-Bordom D-C, Kamarajah S, Christou N. Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines. 2021; 9(8):894. https://doi.org/10.3390/biomedicines9080894

Chicago/Turabian Style

Osei-Bordom, Daniel-Clement, Sivesh Kamarajah, and Niki Christou. 2021. "Colorectal Cancer, Liver Metastases and Biotherapies" Biomedicines 9, no. 8: 894. https://doi.org/10.3390/biomedicines9080894

APA Style

Osei-Bordom, D.-C., Kamarajah, S., & Christou, N. (2021). Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines, 9(8), 894. https://doi.org/10.3390/biomedicines9080894

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop